APAC Imaging Agent Market size is poised to surpass USD 2.7 billion by 2028, according to a latest forecast report by Graphical Research.
The rising number of cardiovascular and cancer populations across the Asia Pacific region will increase the market demand. For instance, according to the Global Burden of Disease study, in 2019, an estimated New cancer cases jumped to over 23 million in 2019 from 18.7 million in 2010. Cancer deaths reached 10 million in 2019 from 8.29 million in 2010. These figures represent an increase of 20.9% and 26.3% respectively. Similarly, according to the International Agency for Research on Cancer, in India, total of 13,24,413 new cases were recorded in 2020. Such factors increase the demand for advanced imaging procedure for disease diagnosis that increases the market growth.
The barium-based contrast media segment surpassed USD 568.8 Million revenue in 2021, attributed to surging use of barium-based contrast agents for various diagnostic X-ray procedures to detect various diseases in the body. Moreover, barium-based contrast media is also used in the fluoroscopic examination of the gastrointestinal tract. This contrast material can be taken orally or by mouth in various forms such as powder, paste, or liquid. Such factors will propel the market size.
The gastrointestinal segment will register 5.4% CAGR during the analysis period, owed to rising prevalence of gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome. Various study revealed that the irritable bowel syndrome (IBS) has become more common in Asian populations. Because of dietary differences, genetic factors, and socio-cultural backgrounds. For instance, according to the data published by National Center for Biotechnology Information (NCBI), in June 2021, irritable bowel syndrome (IBS) affects 2.3% to 15.8% of the Chinese population. such a scenario increases the demand for barium sulfate suspensions and iodinated contrast media to opacify the lumen of the gastrointestinal (GI) tract.
The magnetic resonance imaging (MRI) segment held around 13.6% market share in 2021. Magnetic resonance imaging (MRI) is one of the non-invasive imaging technologies that scan and produces detailed images of the tissues and organs in the body. MRI is usually used to detect multiple sclerosis, brain injury, stroke, epilepsy, and infection. In addition, MRI is also used to evaluate blood vessels and lymph nodes to detect inflammation of the vessels and malformations of the blood vessels.
Browse detailed statistical insights from the report, “Asia Pacific Imaging Agents Market Forecast 2028 By Product Type (Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, Barium-based Contrast Media), By Application (Oncology, Gastrointestinal, Cardiology, Neurology), By Modality (X-Ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound), By End-use (Hospitals, Ambulatory Surgical Centers, Diagnostic & Imaging Centers), Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Taiwan, Malaysia, Indonesia, Thailand), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
The diagnostic & imaging centers segment revenue was over USD 520 million in 2021, owing to the rising innovative technologies to manufacture advanced imaging systems and agents for imaging procedures. These instruments produce visual information about internal organs to diagnose the disease condition in the body. These centers use advanced X-rays, computed tomography (CT), magnetic resonance imaging (MRI) and fluoroscopy to diagnose the disease or illness in an efficient and cost-effective manner. Additionally, rising use of imaging agents in diagnostic centers for diseases treatment will drive the industry growth. This leads to increasing demand of various instruments such as computed tomography and ultrasound for identifying the infected part of the body, tissues or organs.
Japan imaging agent industry will experience 4.3% growth rate during the forecast timeline, due to the rising technological advancement in imaging procedures coupled with increasing launch of innovative contrast agents. For instance, in June 2019, Daiichi Sankyo transferred its marketing authorization rights of four diagnostic imaging agents such as Omnipaque, Omniscan, Visipaque, and Sonazoid to GE Healthcare Pharma Limited in Japan. Throughout the transition, both firms are dedicated to continuing to serve medical facilities with reliable supplies. Similarly, in November 2021, Canon Medical launched new, advanced and productive 1.5T MRI System to monitor and position patients. This features new AI technologies that automatically scan planning for Prostate, Live and Whole Spine.
The APAC imaging agent market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue in USD million from 2017-2028, for the following segments:
Asia-Pacific Market, By Product Type
- Iodinated Contrast Media
- Gadolinium-based Contrast Media
- Microbubble Contrast Media
- Barium-based Contrast Media
Asia-Pacific Market, By Application
Asia-Pacific Market, By Modality
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
Asia-Pacific Market, By End-use
- Ambulatory Surgical Centers
- Diagnostic & Imaging Centers
The above information has been provided for the following countries:
- Asia Pacific
- South Korea